$DWTX News
Last published 1w ago
- 1w agoDWTXDogwood Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoDWTXDogwood Therapeutics Announces Third Quarter 2026 Financial ResultsGlobeNewswire- Completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing
- 3w agoDWTXDogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.GlobeNewswire- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory
- 1mo agoDWTXDogwood to Participate in the 2026 Maxim Growth SummitGlobeNewswireATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy,
- 2mo agoDWTXDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialGlobeNewswire- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX)
- 2mo agoDWTXDogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026GlobeNewswireALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines
- 3mo agoDWTXDogwood Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewswire- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in
- 3mo agoDWTXDogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026GlobeNewswireATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today
- 4mo agoDWTXDogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory BoardGlobeNewswireALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines
- 5mo agoDWTXDogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension StudyGlobeNewswireNew study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron®
- 6mo agoDWTXDogwood Therapeutics Announces First Quarter 2026 Financial ResultsGlobeNewswire- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced
- 6mo agoDWTXDogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026GlobeNewswireATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it
- 6mo agoDWTXDogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100MGlobeNewswire- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net
- 7mo agoDWTXDogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and NeuropathyGlobeNewswireDogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the
- 9mo agoDWTXDogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026GlobeNewswire- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc.
- 10mo agoDWTXDogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b DevelopmentGlobeNewswirePricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc.
- 10mo agoDWTXDogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic PainGlobeNewswire- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates
- 11mo agoDWTXDogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045ACCESS Newswire- New Composition of Matter Intellectual Property Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-- New Synthetic Process to be Used for Phase 3 Development Provides
- 1y agoDWTXDogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025ACCESS Newswire- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood
- 1y agoDWTXDogwood Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive
- 1y agoDWTXDogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025ACCESS NewswireATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. , a development‐stage biotechnology company developing new medicines to treat pain and neuropathy,
- 1y agoDWTXDogwood Therapeutics to Participate at the Maxim Growth Summit 2025ACCESS NewswireATLANTA, GA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. , a development-stage biotechnology company developing new medicines to treat pain and neuropathic
- 1y agoDWTXDogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics SummitACCESS NewswireATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. , a development-stage biotechnology company developing new medicines to treat pain, today announced
- 1y agoDWTXDogwood Therapeutics, Inc. Investor Call - DOGWOOD THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to today's Dogwood Therapeutics Incorporated Investor Call. At this time, all participants have been placed in a listen-only mode, and please be advised that today's call is being recorded at th
- 1y agoDWTXDogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer PatientsGlobeNewswire-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026-
- 1y agoDWTXDogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders,
- 1y agoDWTXDogwood Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswire- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track for Q4 2025 - -
- 1y agoDWTXDogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b TrialGlobeNewswire- Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35
- 1y agoDWTXDogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025GlobeNewswireATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders,
- 1y agoDWTXDogwood Therapeutics to Present at Sidoti Small-Cap Virtual ConferenceGlobeNewswireATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related
- 1y agoDWTXDogwood Therapeutics Announces First Quarter 2025 Financial ResultsGlobeNewswire- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data
- 1y agoDWTXDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceGlobeNewswireATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related
- 1y agoDWTXDogwood Therapeutics, Inc. Regains Nasdaq ComplianceGlobeNewswireATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related
- 1y agoDWTXDogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4
- 1y agoDWTXDogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic PainGlobeNewswireATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid,
- 1y agoDWTXDogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewswireProceeds from today's financing, when added to existing cash, fund operations through Q1 2026 The Company is planning to announce interim data from its ongoing Halneuron® Phase 2b chemotherapy induced neuropathic
- 1y agoDWTXDogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving ForwardGlobeNewswireATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid,
- 1y agoDWTXDogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025GlobeNewswireATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor
- 1y agoDWTXDogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated StudyGlobeNewswire- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – - Top-line
- 2y agoDWTXDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsGlobeNewswire- Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the "Combination") -
- 2y agoDWTXDogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024GlobeNewswireATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report
- 2y agoDWTXDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it has regained
- 2y agoVIRIDWTXVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX")GlobeNewswireStrategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25